Speaker(s):
Sara Gaines, PharmD, Hepatology MTM Pharmacist, Geisinger - has nothing to disclose.
Moderator(s):
Leonie Vachon, NP, Western Region GI APP Chief, Geisinger - has nothing to disclose.
Learning Objectives:
At the conclusion of this session, the participant should be able to:
- Classify patients using AASLD’s new steatotic liver disease terminology
- Recognize medications newly approved to treat hepatologic conditions
- Evaluate the appropriateness of these new medications in patient case
Disclosure of Relevant Financial Relationships with/without Commercial Interests:
The Planning Committee consisting of Karla Leschinsky, PA-C, Leonie Vachon, CRNP, Hannah Clark, RN, Alyssa Jones, PharmD, and Lorella Thomas, CRNP have no identified disclosures.
CE Committee Member/Content Reviewers have nothing to disclose.
Any/All relevant financial relationships have been mitigated.
Content Disclosure:
This presentation/content is HIPAA compliant.
Commercial Support for this Session
None
- 1.00 AAPA Category I CME
- 1.00 ACPE
- 1.00 ANCC
- 1.00 Participation Credit